Cancer anti-hormonal therapies

Anti-hormone Therapy Principles of Endocrine Therapy of Cancer... 

Hoffmann J, Sommer A (2007) Anti-hormone Therapy Principles of Endocrine Therapy of Cancer. 1 1-64... 

We survivors need to know that this can and does happen. I would still make the same decisions in my treatment plan, but I would better be able to deal with the fallout of the brain freeze. —Unemployed, formerly worked with the developmentally and mentally Impaired. Breast cancer, stage , diagnosed in 2005 at age fifty. (Treatment mastectomy. Chemo doxorubicin, cyclophosphamide, and paclitaxel. Targeted therapy trastuzumab (Herceptin). Anti-hormonal therapies tamoxifen and anastrozole.)... 

The encapsulation of hepatocytes for a bioartificial liver, and cell therapy for the treatment of other hormone deficiencies or neurodegenerative diseases, such as Alzheimer s and Parkinson s, are also under investigation. Additional examples of cell encapsulation in polymer-polymer coacervates include non-autologous gene therapy,blood substitutes as well as the treatment of prostate cancer. Pharmaceutical applications of microcapsules encompass, in addition, trans-dermal drug delivery and protein delivery such as is required in anti-inflammatory therapy for arthritis. 

The anti-estrogen, tamoxifen, is the most commonly used hormonal therapy for breast cancer and has demonstrated positive effects on the cardiovascular and skeletal systems of postmenopausal women but is associated with an increased risk of uterine cancer. Tamoxifen is described as a SERM, a selective estrogen receptor modulator with a tissue selective profile that is caused by the different distribution of the a- and /3-subtypes of the estrogen receptor (ERa and ER/3) that activate and inhibit transcription respectively (77). These selective effects have been ascribed to differential interactions with gene promotor elements and coregulatory proteins depending on whether the ERa interacts directly, or in a tethered manner with DNA (78). In uterine tissue, tamoxifen interacts with a specific coactivator, SRCl, that is abundant in uterine tissue. 

---